Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402207 | 0.86 | GRM2 (0.41) | CYP1A2NPC1RAB9ASMN1; SMN2HTR1A | |
| SCHEMBL403323 | 0.85 | TAAR1 (0.49) | TAAR1CYP1A2TP53NPC1CYP3A4 | |
| SCHEMBL402232 | 0.83 | TAAR1 (0.54) | TAAR1CYP1A2TP53NPC1CYP3A4 | |
| SCHEMBL400768 | 0.81 | TAAR1 (0.56) | TAAR1CYP1A2TP53CYP2D6MAPT | |
| SCHEMBL29714039 | 0.81 | TAAR1 (0.56) | TAAR1CYP1A2TP53CYP2D6MAPT | |
| SCHEMBL399119 | 0.80 | TAAR1 (0.50) | TAAR1CYP1A2TP53NPC1CYP3A4 | |
| SCHEMBL545356 | 0.79 | CYP1A2 (0.56) | TAAR1CYP1A2CYP2D6MAPTHTR1A | |
| SCHEMBL545074 | 0.79 | EPHX2 (0.56) | TAAR1CYP1A2TP53NPC1CYP2D6 | |
| SCHEMBL3189494 | 0.78 | FAAH (0.56) | TAAR1CYP1A2CYP2D6MAPTHTR1A | |
| SCHEMBL401653 | 0.78 | CYP1A2 (0.50) | TAAR1CYP1A2NPC1CYP2D6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | claimed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | claimed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | claimed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | claimed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | claimed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | claimed |
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | TAAR1 4240/4885CYP1A2 3816/4885TP53 3457/4885 |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | TAAR1 4458/4885CYP1A2 4402/4885TP53 2477/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | TAAR1 4246/4885CYP1A2 4679/4885TP53 3941/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | TAAR1 2606/4885CYP1A2 4662/4885TP53 1007/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | TAAR1 4657/4885CYP1A2 4662/4885TP53 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.